Collagen-hydroxyapatite/tricalcium phosphate microspheres as a delivery system for recombinant human transforming growth factor-beta 1.
The purpose of this study is to evaluate the carrier capability of collagen-hydroxyapatite/tricalcium phosphate (Col-HA/TCP) microspheres to the rhTGF-beta 1 (recombinant human transforming growth factor-beta 1). After anesthesia, a bone defect (7.0 mm in diameter and 10.0 mm in depth) was created at the distal femoral condyles of New Zealand white rabbits. These defects were then completely filled with the implant materials. After 5, 7, 9, 11, 13, and 15 weeks, the animals were sacrificed and histological evaluations were performed. The results showed that when the defects were treated with Col-HA/TCP microspheres without rhTGF-beta 1, there was only spotty new bone formation during the 15 week experimental period and most of the defect was filled with fibrous tissue and inflammatory cells, whereas active bone formation with mature marrow tissue formation was evident in the defect treated with Col-HA/TCP microspheres containing rhTGF-beta 1. Collagen-hydroxyapatite/tricalcium phosphate microspheres were expected to be replaced by the regenerated bone structure as the bone reconstruction and bone-remodeling process occurred. It was apparent that bone regeneration was influenced by the addition of rhTGF-beta 1. Collagen-hydroxyapatite/tricalcium phosphate microspheres were a good carrier for rhTGF-beta 1.
Sun
Jui-Sheng
JS
Department of Orthopedic Surgery, National Taiwan University Hospital, Taiwan, ROC. drjssun@ccms.ntu.edu.tw
Lin
Feng-Huei
FH
Wang
Yng-Jiin
YJ
Huang
Yi-Chau
YC
Chueh
Shan-Chang
SC
Hsu
Fu-Yin
FY
D000818:Animals; D001861:Bone Regeneration; D002130:Calcium Phosphates; D003094:Collagen; D004337:Drug Carriers; D016503:Drug Delivery Systems; D017886:Durapatite; D005269:Femur / Q000473:pathology; D008297:Male; D008863:Microspheres; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*; D053773:Transforming Growth Factor beta1; D014945:Wound Healing
D002130:Calcium Phosphates; D004337:Drug Carriers; D011994:Recombinant Proteins; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C485817:beta-tricalcium phosphate; D003094:Collagen; D017886:Durapatite; C018392:tricalcium phosphate